SEARCH

SEARCH BY CITATION

References

  • 1
    Travis WD, Branbilla E, Muller-Hermelink HK. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004.
  • 2
    Filosso PL, Ruffini F, Asioli S et al. Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. Lung Cancer 2011; 74: 2529.
  • 3
    Cooke DT, Nguyen DV, Yang Y et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010; 90: 943948.
  • 4
    Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 14971500.
  • 5
    Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 21292139.
  • 6
    Pao W, Miller VA. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 16: 22562268.
  • 7
    Mitsudomi T, Kosaka T, Yatabe Y et al. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11: 190198.
  • 8
    Sasaki H, Endo K, Fujii Y et al. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 2007; 55: 129130.
  • 9
    Kang SM, Kang HJ, Shin JH et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007; 109: 581587.
  • 10
    Sobin L, Wittekind C. TNM Classification of Malignant Tumors. New York: Wiley and Sons, 2002.
  • 11
    Tsuta K, Ishii G, Nitadori J et al. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 2006; 209: 7887.
  • 12
    Shigematsu H, Lin L, Gazdar AF et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339346.
  • 13
    Kancha RK, Peschel C, Duyster J et al. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol 2011; 6: 387392.
  • 14
    Ohtsuka K, Ohnishi H, Fujiwara M et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: Tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007; 109: 741750.
  • 15
    Toyooka S, Yatabe Y, Tomii K et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006; 118: 15881590.
  • 16
    Tochigi N, Dacic S, Nikiforova M et al. Adenosquamous carcinoma of the lung: A microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol 2011; 135: 783789.
  • 17
    Jia XL, Chen G et al. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 2011 May 17(Epub) 74: 396400.
  • 18
    Kozu Y, Tsuta K, Kohno T et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011; 73: 4550.
  • 19
    Yu J, Kane S, Wu J et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 30233028.
  • 20
    Li D, Chen S, Hu C et al. Immunohistochemistry with mutation specific antibodies detecting the status of EGFR mutations in non-small-cell lung cancer. Mod Pathol 2010; 23: 407A.
  • 21
    Kato Y, Peled N, Wynes MW et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010; 5: 15511558.
  • 22
    Kitamura A, Hosoda W, Yatabe Y et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010; 16: 33493355.
  • 23
    Miyamae Y, Shimizu K, Hirato J et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011; 25: 921928.
  • 24
    Rekhtman N, Paul K, Marc L et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous cell carcinoma of lung: Lack of EGFR/KRAS and preence of PIK3CA/ALT1 mutaions. Clin Cancer Res 2012; 18: 11671176.
  • 25
    Kanazawa H, Ebina M, Nukiwa T et al. Transition frm squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung. Am J Pathol 2000; 156: 12891298.
  • 26
    Blons H, Cote JF, Le CD et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol 2006; 30: 13091315.
  • 27
    Fukuoka M, Wu YL, Mok TS et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 28662874.
  • 28
    Sonobe M, Kobayashi M, Date H et al. Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. Ann Surg Oncol 2011; May 24; 19: 347353.
  • 29
    Mitsudomi T, Kosaka T, Yatabe Y et al. Mutation of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 25132520.
  • 30
    Shukuya T, Takahashi T, Yamamoto N et al. Efficacy of gefitinib for non-adenocarcinoma non-small cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of previous reports. Cancer Sci 2011; 102: 10321037.